Omalizumab Combined with Cyclosporine for the Treatment and Management of Refractory Urticarial Vasculitis

Xinlong Chen,1 Qiao Yu,1 Degui Chang,2 Lisha Sun3 1Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 2Department of Urology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 3Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of ChinaCorrespondence: Lisha Sun, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China, Email sunlisha2025@163.comAbstract: Urticarial vasculitis (UV) is a clinicopathologic entity characterized by urticarial lesions disclosing histopatho logically leukocytoclastic vasculitis, mainly of postcapillary venules. A 61-year-old woman with a four-month history of widespread, pruritic urticarial lesions was diagnosed with urticarial vasculitis. The patient received a subcutaneous injection of Omalizumab (300 mg) every 28 days, combined with oral Cyclosporine (3 mg/kg/day). Significant clinical improvement was noted within five days post-treatment. This case highlights the difficulties in treating refractory urticarial vasculitis while demonstrating the successful use of Omalizumab plus Cyclosporine, providing a viable treatment option for similar patients.Keywords: omalizumab, cyclosporine, urticarial vasculitis